{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T11:12:19Z","timestamp":1763809939427,"version":"build-2065373602"},"reference-count":17,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T00:00:00Z","timestamp":1543190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Botulism, caused by exposure to one or more of the eight serotypes of botulinum neurotoxins (BoNTs) (BoNT\/A through H), is often fatal without rapid treatment. [...]<\/jats:p>","DOI":"10.3390\/toxins10120495","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T03:31:33Z","timestamp":1543289493000},"page":"495","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Botulinum Neurotoxins (BoNTs)\u2014Antibody and Vaccine"],"prefix":"10.3390","volume":"10","author":[{"given":"Jianlong","family":"Lou","sequence":"first","affiliation":[{"name":"Department of Anesthesia and Perioperative Care, University of California, San Francisco, Zuckerberg San Francisco General Hospital and Trauma Center, Room 3C-38, 1001 Potrero Avenue, San Francisco, CA 94110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"Marks","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Perioperative Care, University of California, San Francisco, Zuckerberg San Francisco General Hospital and Trauma Center, Room 3C-38, 1001 Potrero Avenue, San Francisco, CA 94110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,11,26]]},"reference":[{"key":"ref_1","unstructured":"Sifferlin, A. (2018, November 24). Botox: The Drug That\u2019s Treating Everything. Available online: http:\/\/time.com\/4623409\/botox-drug-treating-everything\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.toxicon.2009.03.021","article-title":"Basic and clinical aspects of BOTOX\u00ae","volume":"54","author":"Brin","year":"2009","journal-title":"Toxicon"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.toxicon.2008.11.013","article-title":"Disease-oriented approach to botulinum toxin use","volume":"54","author":"Jankovic","year":"2009","journal-title":"Toxicon"},{"key":"ref_4","unstructured":"Broad, W.J. (2018, November 24). SOWING DEATH: A Special Report; How Japan Germ Terror Alerted World. Available online: http:\/\/www.nytimes.com\/1998\/05\/26\/world\/sowing-death-a-special-report-how-japan-germ-terror-alerted-world.html."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","article-title":"Botulinum toxin as a biological weapon","volume":"285","author":"Arnon","year":"2001","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Sundeen, G., and Barbieri, J.T. (2017). Vaccines against Botulism. Toxins, 9.","DOI":"10.3390\/toxins9090268"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Rasetti-Escargueil, C., Avril, A., Miethe, S., Mazuet, C., Derman, Y., Selby, K., Thullier, P., Pelat, T., Urbain, R., and Fontayne, A. (2017). The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum Antibodies. Toxins, 9.","DOI":"10.3390\/toxins9100309"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lou, J., Wen, W., Conrad, F., Meng, Q., Dong, J., Sun, Z., Garcia-Rodriguez, C., Farr-Jones, S., Cheng, L.W., and Henderson, T.D. (2018). A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A. Toxins, 10.","DOI":"10.3390\/toxins10020084"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Garcia-Rodriguez, C., Razai, A., Geren, I.N., Lou, J., Conrad, F., Wen, W.H., Farr-Jones, S., Smith, T.J., Brown, J.L., and Skerry, J.C. (2018). A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes. Toxins, 10.","DOI":"10.3390\/toxins10030105"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Derman, Y., Selby, K., Miethe, S., Frenzel, A., Liu, Y., Rasetti-Escargueil, C., Avril, A., Pelat, T., Urbain, R., and Fontayne, A. (2016). Neutralization of Botulinum Neurotoxin Type E by a Humanized Antibody. Toxins, 8.","DOI":"10.3390\/toxins8090257"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Rosen, O., Ozeri, E., Barnea, A., David, A.B., and Zichel, R. (2016). Development of an Innovative in Vitro Potency Assay for Anti-Botulinum Antitoxins. Toxins, 8.","DOI":"10.3390\/toxins8100276"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Torgeman, A., Ozeri, E., Ben David, A., Diamant, E., Rosen, O., Schwartz, A., Barnea, A., Makovitzki, A., Mimran, A., and Zichel, R. (2017). Role of Homologous Fc Fragment in the Potency and Efficacy of Anti-Botulinum Antibody Preparations. Toxins, 9.","DOI":"10.3390\/toxins9060180"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Al-Saleem, F.H., Sharma, R., Puligedda, R.D., Elias, M., Kattala, C.D., Simon, P.M., Simpson, L.L., and Dessain, S.K. (2017). RBC Adherence of Immune Complexes Containing Botulinum Toxin Improves Neutralization and Macrophage Uptake. Toxins, 9.","DOI":"10.3390\/toxins9050173"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Bak, N., Rajagopal, S., Stickings, P., and Sesardic, D. (2017). SiMa Cells for a Serotype Specific and Sensitive Cell-Based Neutralization Test for Botulinum Toxin A and E. Toxins, 9.","DOI":"10.3390\/toxins9070230"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Webb, R.P., Smith, T.J., Smith, L.A., Wright, P.M., Guernieri, R.L., Brown, J.L., and Skerry, J.C. (2017). Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism. Toxins, 9.","DOI":"10.3390\/toxins9090269"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Otaka, D.Y., Barbosa, J.D., Moreira, C., Ferreira, M.R.A., Cunha, C.E.P., Brito, A.R.S., Donassolo, R.A., Moreira, \u00c2.N., Concei\u00e7\u00e3o, F.R., and Salvarani, F.M. (2017). Humoral Response of Buffaloes to a Recombinant Vaccine against Botulism Serotypes C and D. Toxins, 9.","DOI":"10.3390\/toxins9100297"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Chang, H.J., Hong, B.Y., Lee, S.J., Lee, S., Park, J.H., and Kwon, J.Y. (2017). Efficacy and Safety of Letibotulinum Toxin A for the Treatment of Dynamic Equinus Foot Deformity in Children with Cerebral Palsy: A Randomized Controlled Trial. Toxins, 9.","DOI":"10.3390\/toxins9080252"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/10\/12\/495\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:32:03Z","timestamp":1760196723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/10\/12\/495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,26]]},"references-count":17,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["toxins10120495"],"URL":"https:\/\/doi.org\/10.3390\/toxins10120495","relation":{},"ISSN":["2072-6651"],"issn-type":[{"type":"electronic","value":"2072-6651"}],"subject":[],"published":{"date-parts":[[2018,11,26]]}}}